This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chierchia, S. Articles by Maseri, A. Search for Related Content PubMed PubMed Citation Articles by Chierchia, S. Articles by Maseri, A.

Circulation, Vol 65, 470-477, Copyright © 1982 by American Heart Association

ARTICLES

Effects of intravenous prostacyclin in variant angina

S Chierchia, C Patrono, F Crea, G Ciabattoni, R De Caterina, GA Cinotti, A Distante and A Maseri

A lack in prostacyclin (PGI2) production due to atherosclerosis may play a role in the pathophysiology of some of the clinical manifestations of ischemic heart disease and in particular, of coronary vasospasm. We therefore evaluated the effects of i.v. PGI2 in nine patients with variant angina and six normal volunteers. In normal subjects, PGI2 (2.5, 5, 10 and 20 micrograms/kg/min) had significant antiplatelet effects, caused a dose-dependent decrease in both systolic and diastolic arterial pressure and a decrease in pulmonary resistance. Heart rate increased in a dose-dependent manner, but no consistent effects on myocardial contractility (evaluated by ultrasound) were observed. Side effects were negligible and readily reversible. Although producing obvious antiplatelet and vasodilatory effects, PGI2 did not affect the number, severity and duration of spontaneous ischemic episodes due to coronary vasospasm in five patients and ergonovine- induced spasm in three. However, the number of ischemic episodes was consistently reduced in one patient during four consecutive periods of PGI2 infusion alternated with placebo. a severe, prolonged ischemic episode with ST elevation and pain was consistently observed in this patient every time PGI2 was discontinued. In the appropriate environment, PGI2 can be administered safely to patients with ischemic heart disease. Occasionally, PGI2 may result in a complete disappearance of ischemic episodes due to coronary vasospasm, but usually it is ineffective. These conflicting results could be related to different etiologies of coronary spasm.

This article has been cited by other articles:

				Y. Aizawa, S. Niwano, M. Aizawa, M. Tamura, and A. Shibata Attenuation of the Vasoconstrictor Action of Neuropeptide-Y by Calcium-Channel Blockers Angiology, October 1, 1989; 40(10): 890 - 894. [Abstract] [PDF]

				S. Miyajima, Y. Aizawa, and A. Shibata Attenuation of Reactive Hyperemia Caused by Aspirin in Canine Coronary Artery Angiology, September 1, 1989; 40(9): 824 - 829. [Abstract] [PDF]